LITOM Pcs 4 Solar 270° Light Sensor Motion Solar Waterproof Outdoor,IP67 Lights Landscape & Walkway Lights


  1. Home
  2. LITOM Pcs 4 Solar 270° Light Sensor Motion Solar Waterproof Outdoor,IP67 Lights
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
4 Pcs LITOM Solar Lights Outdoor,IP67 Waterproof Solar Motion Sensor Light 270°
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is ISBN:

Does not apply

EAN:

Does not apply

Modified Item: No
Power Source: Solar Custom Bundle: No
MPN:

Does not apply

Material: Plastic
Brand:

LITOM

UPC:

Does not apply

Bulb Type: PIR







published on tue nov 09 2021

LITOM Pcs 4 Solar 270° Light Sensor Motion Solar Waterproof Outdoor,IP67 Lights Landscape & Walkway Lights

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

LITOM Pcs 4 Solar 270° Light Sensor Motion Solar Waterproof Outdoor,IP67 Lights Landscape & Walkway Lights

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS